From here.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) fell $5.25 (13%) to $33.99 on Tuesday after FDA requested additional information from the company about the existing data set for eteplirsen to "inform a decision" on whether the data could support accelerated approval for Duchenne muscular dystrophy (DMD). Sarepta said FDA made the request at a March end-of-Phase II meeting to discuss a potential NDA for the phosphorodiamidate morpholino oligomer (PMO) that induces exon 51 skipping on the dystrophin gene.
Well for me (and I am professional in the pharmaceutical field) the words "the phosphorodiamidate morpholino oligomer (PMO) that induces exon 51 skipping on the dystrophin gene" sound as a unprehensible rocket science. Very often too over-complicated concepts do not work - exactly like in the present case...
No comments:
Post a Comment